

**Newsletter on current research
in medicine and health no.450,**
26 February, 2026



IDIVAL support programmes will exceed €1.5 million in 2026
[Read More](#)



Robotic surgery and intracorporeal anastomosis improve quality of life after right colon cancer surgery
[Read More](#)



IDIVAL and the Cantabrian Health Service promote a comprehensive and community-based approach to prevent frailty
[Read More](#)

CONFERENCES



SAVE THE DATE

Fecha: 24 de abril de 2026
Lugar: Fundación Botín, C. Pedruca, 1 (Santander)

4th edition of the National Forum on Innovation Management in Health – Building Minds
[Read More](#)



Forum – ‘Precision Medicine in Patient Safety’

[Read More](#)



Forum – “Beyond Immunization: Vaccinology Course” 2nd Edition

[Read More](#)

CALLS FOR APPLICATIONS

NEXT-VAL PROGRAM

Open From March 2, 2026 to April 1, 2026

Second Call for São Paulo – Spain Cooperation Proposals in R&D&I Projects 2026

Open until March 31, 2026

32nd Edition of the Rafael Hervada Award for Biomedical Research

Open until September 30, 2026

All Calls

THESIS

Impact of an Uncontrolled Donation After Circulatory Death Program on Kidney Transplantation

Sandra Campos Fernández – March 5

Association Between the Oxidative Potential of Particulate Matter Collected by Personal Samplers and Systemic Inflammation in Adult Patients with Asthma

Juan José Ruiz Cubillán – March 16

Systematic Analysis of Rhetorical Structure and Authorial Voice in the Introductions of Research Articles from Four Medical Subdisciplines

María Paula Roverso – March 25

PUBLICATIONS

Axitinib and Long-Acting Octreotide in Advanced Extrapancratic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (Axinet, Getne 1107)

Journal of Clinical Oncology

IMMUNONET: A multicenter, open-label, proof-of-concept phase II trial evaluating NP137 as add-on therapy in advanced/metastatic solid tumors treated with standard immunotherapies

Journal of Clinical Oncology

KEYNOTE-859: 4.5-year median follow-up of pembrolizumab plus chemotherapy for previously untreated advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

Journal of Clinical Oncology

All Publications

Visit Our Web

INSTITUTO DE INVESTIGACIÓN MARQUÉS DE VALDECILLA, Edificio IDIVAL, Avenida Cardenal Herrera Oria s/n, Santander, (CANTABRIA) 39011, España, 942 31 55 15

[Gestionar preferencias](#)

[Ver Política de Privacidad](#)

